May 23, 2024 · Form 4 insider transaction
Retter Andrew bought 100,000 shares of VOLITIONRX LTD at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4.
In connection with his employment as Chief Medical Officer of Volition Diagnostics UK Limited, Dr. Retter received restricted stock units ("RSUs") subject to a 3-year vesting schedule, vesting as to 33,334 units, 33,333 units, and 33,333 units on each of May 23, 2025, May 23, 2026 and May 23, 2027, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.